🫁Dirozalkib yielded promising efficacy among patients with ALK-positive NSCLC.

ESMO Congress 2026
October 23–27, 2026 · Madrid · 176 items
ALK
0 people · 0 posts
Floor
x.com@Score6060
BioWorld@BioWorldScore6060 #AACR26: Xuanzhu shares dip despite phase III ALK inhibitor data
Nelson Santos@Nelson7SantosScore6060 Nelson Santos@Nelson7SantosScore6060 Nelson Santos@Nelson7SantosScore6060
ALK Positive@ALKPositiveincScore6060 ALK Positive is at #AACR26 in San Diego!